Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
作者信息
Pietrantonio F, Garassino M C, Torri V, de Braud F
机构信息
Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
出版信息
Ann Oncol. 2012 Oct;23(10):2771-2772. doi: 10.1093/annonc/mds332. Epub 2012 Aug 8.
PMID:22875835
Abstract
摘要
Zotero 插件